Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease

Movement Disorders

Volumn 12, Issue 3, 1997, Pages 285-292

  Nutt, John G ^a,b,c   Carter, Julie H ^a,b   Lea, Eric S ^a   Woodward, William R ^a,b  

^a School of Medicine   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Department of Neurology ^*  (United States)

Author keywords

Large neutral amino acids; Levodopa; Motor fluctuations; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; AMANTADINE; AMINO ACID; ANTIPARKINSON AGENT; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; SELEGILINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG INFUSION; DYSKINESIA; FEMALE; HUMAN; MALE; MOTOR ACTIVITY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; STAGING;

ADULT; AGED; AMINO ACIDS; ANTIPARKINSON AGENTS; BRAIN; CARBIDOPA; CIRCADIAN RHYTHM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEVODOPA; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0030914778     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120304     Document Type: Article

References (33)

1. Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Amt Neural 1988;24:372-8.
2. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neural 1990;27:18-23.
3. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-44.
4. Gancher ST, Nutt JG, Woodward WR. Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations. Neurology 1988:38:712-6.
5. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon. Arch Neural 1992;49:1123-30.
6. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neural 1987:22:475-9.
7. Schuh LA, Bennett JP. Suppression of dyskinesia in advanced Parkinson's disease I. Continuous intravenous levodopa shifts dose response for production of dyskinesia but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-50.
8. Nutt JG, Woodward WR, Hammerstad JP, et al. The "onoff" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N EngU Med 1984,10:483-8.
9. Nutt JG, Woodward WR, Carter JH. Clinical and biochemical studies with controlled-release levodopa/carbidopa. Neurology 1986;36:1206-11.
10. Jones BJ, Gilligan JP. o-Phthaldialdehyde precolumn derivatization and reversed-phase high-performance liquid chromotagraphy of polypeptide hydrolysates and physiological fluids. J Chromatogr 1983;266:471-82.
11. Nutt JG, Carter JH, Woodward WR, et al. Does tolerance develop to levodopa? Comparison of 2- and 21-hour levodopa infusions. Mov Disord 1993;8:139-43.
12. Nutt JG, Woodward WR, Carter JH, Trotman T. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neural Neurosurg Psychiatry 1989;52:481-7.
13. Pincus JH, Barry KM. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neural 1987;44:1006-9.
14. Carter JH, Nutt JG, Woodward WR. The effect of exercise on levodopa absorption. Neurology 1992;42:2042-5.
15. Kuruma I, Bartholini G, Tissot R, Pletscher A. The metabolism of L-3-O-methyldopa, a precursor of dopa, in man. Clin Pharmacol Ther 1971;12:678-82.
16. Sharpless NS, Muenter MD, Tyce GM, Owen CA. 3-Methoxy4-hydroxyphenylaIanine (3-O-methyldopa) in plasma during oral L-DOPA therapy of patients with Parkinson's disease. Clin Chim Acta 1972;37:359-69.
17. Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-OMethyldopa and the response to levodopa in Parkinson's disease. Ann Neural 1987;21:584-8.
18. Cedarbaum JM, Kutt H, McDowell FH. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988;38:533-6.
19. Fabbrini G, Juncos JL, Mouradian MM, et al. 3-O-Methyldopa and motor fluctuations in Parkinson's disease. Neurology 1987;37:856-9.
20. Guttman M, Leger M, Cedarbaum JM, et al. 3-O-Methyldopa administration does not alter fluorodopa transport into brain. Ann Neural 1992;31:638-43.
21. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-9.
22. Feigin RD, Klainer AS, Beisel WR. Factors affecting circadian periodicity of blood amino acids in man. Metabolism 1968;17:764-75.
23. Fernstrom JD, Wurtman RJ, Hammarstrom-Wiklund B, et al. Diurnal variations in plasma concentrations of tryptophan, tyrosine and other neutral amino acids: effect of dietary protein intake. Am J Clin Nutr 1979;32:1912-22.
24. Gancher ST, Null JG, Woodward WR. Time-course of tolerance to apomorphine in parkinsonism. Clin Pharmacol Ther 1992:52:504-10.
25. Marsden CD. "On-off" phenomena in Parkinson's disease. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson's disease: current progress, problems and management. Amsterdam: Elsevier/North-Holland Biomedical Press, 1980:241-54.
26. Rusk GD, Siemers ER. Diurnal variation in motor ability in Parkinson's disease [Abstract]. Ann Neural 1993;34:266-7.
27. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1992;41:174-81.
28. Hanvood G, Hierons R, Fletcher NA, Marsden CD. Lessons from a remarkable family with dopa-responsive dystonia. J Neural Neurosurg Psychiatry 1994;57:460-3.
29. Frankel JP, Pirtosek Z, Kempster PA, et al. Diurnal differences in response to oral levodopa. J Neural Neurosiirg Psychiatry .1990;53:948-50.
30. Davis TL, Brughitta G, Baronti F, Mouradian MM. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991:41:630-3.
31. Contin M, Riva R, Martinelli P, Baruzzi A. Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease. Mov Disord 1992;7:244-8.
32. Gancher ST, Nutt JG. Diurnal responsiveness to apomorphine. Neurology 1987:37:1250-3.
33. Berry EM, Growdon JH, Wurtman JJ, et al. A balanced carbohydrate-protein diet in the'management of Parkinson's disease. Neurology 1991;41:1295-7.